

# Poster presentations

All posters will be on display throughout the Conference, from 08:00 Sunday 28 October until 17:00 Monday 29 October.

Poster boards are numbered sequentially and located throughout the conference foyer area.

Posters have been grouped thematically and presenters have been asked to be in attendance near their poster during one lunch break, as listed below, to discuss their work with interested delegates.

## Sunday 28 October, 11:45-12:40

- A. Pharmacoepidemiology and Pharmacovigilance research methods
- C. Drug safety risk monitoring, evaluation and prevention
- E. Evidence-based medicine
- G. Drug utilization evaluation studies
- I. Pharmacoepidemiology and traditional medicines

## Monday 29 October, 12:00-13:10

- B. Post-marketing drug effectiveness and safety evaluation
- D. Pharmacogenomics research and drug safety
- F. Evidence-based pharmacy
- H. Rational drug use

## Sunday 28 October 2018

Poster number	Paper title and presenter
<b>A. Pharmacoepidemiology and Pharmacovigilance research methods</b>	
200	<b>A note on the propensity score in observational studies of time-varying treatment with limited overlap</b> Shiro Tanaka, Kyoto University, Japan
201	<b>A methodological review of observational studies on psychotropic drug use in pregnancy and central nervous system outcomes in children</b> Zixuan Wang, University College London, UK
202	<b>The association between prenatal antipsychotics exposure and adverse obstetric and offspring outcomes: a systematic review and meta-analysis</b> Zixuan Wang, University College London, UK
203	<b>The weight-losing effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis</b> Yao Chen, Peking University, China
204	<b>Rates of all-cause community-acquired pneumonia among adult population in Taiwan</b> Edward Kuo, Pfizer Inc, Taiwan
205	<b>Assessment of various risk factors of myocardial infarction in a tertiary care hospital in south India</b> Alekhya Lavu, Manipal College of Pharmaceutical Sciences, India
206	<b>Post-licensure surveillance of Human Papilloma Virus (HPV) vaccine using disproportionality analysis in Vaccine Adverse Event Reporting System (VAERS)</b> Subeesh Viswam, M.S. Ramaiah University of Applied Sciences, India
207	<b>A study to assess the impact of education on HPV infection and vaccination among parents by educating their adolescent girls</b> Rony Abraham, JSS College of Pharmacy, India
208	<b>Drug safety signal detection in regional healthcare database using the Tree-based Scan Statistic and its applicability in 4 settings</b> Hailong Li and Siyan Zhan, West China Second University Hospital, China
209	<b>GLP-IRAs and risk of Diabetic Retinopathy: analysis of the FDA Adverse Event Reporting System Database</b> Wenchao Lu, Peking University, China
210	<b>Improvement of personal level identifiers is imperative in Japanese National Database: a research using claims data of corporate insurances</b> Kiyoshi Kubota, NPO Drug Safety Research Unit, Japan
211	<b>Multiple imputation of clinical variables in fee-for-service medicare population</b> Tiansheng Wang, University of North Carolina at Chapel Hill, USA
212	<b>Relationship of the potential companion diagnostic markers, BRM promoter insertion polymorphisms, and baseline cancer risk and prognosis</b> Geoffrey Liu, Princess Margaret Cancer Centre, University of Toronto, Canada



Poster number	Paper title and presenter
<b>C. Drug safety risk monitoring, evaluation and prevention</b>	
225	<b>A review on methodological quality of current clinical trials of traditional Chinese medicine</b> Zhi Cui, University of Macau, China
226	<b>An analysis of the cognitive status of ADRs in China and the best way to educate patients about ADRs</b> Wei-Xia Zhang, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China
227	<b>Predicting the severity of adverse drug reactions - the role of data mining</b> Yan Li, University of Electronic Science and Technology, China
228	<b>Adverse effects of pharmacotherapy and treatment adherence in patients of the profile outpatient register</b> Nadezda Dmitrieva, National Medical Research Center for Preventive Medicine, Russian Federation
229	<b>DPP4i and risk of inflammatory bowel disease: analysis of the FDA Adverse Event Reporting System</b> Dandan Li, Beijing Friendship Hospital, Capital Medical University, China
230	<b>Attitudes and perceptions towards hypoglycaemia in patients with diabetes mellitus: a multinational cross-sectional study</b> Abdallah Y Naser, University College London, UK
231	<b>Clinical features of drug-induced liver injury: a systematic analysis of the Chinese literature including 15336 patients</b> Chen Pan, Beijing Friendship Hospital, Capital Medical University, China
232	<b>Epidemiology of delayed onset hypersensitivity reactions after administration of low osmolar iodinated contrast media</b> Dong Yoon Kang, Seoul National University, South Korea
233	<b>Breastfed infants' adverse reactions caused by drugs in milk: an analysis of case reports in China from 1974 to 2017</b> Wei Kai, Wuhan General Hospital of PLA, China
234	<b>Impact of medical conditions and medication use during pregnancy on adverse birth outcomes: a hospital-based case-control study</b> Krishna Undela, JSS College of Pharmacy, JSS Academy of Higher Education & Research, India
235	<b>Factors affecting ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated curatively with cisplatin-based chemoradiation</b> Geoffrey Liu, Princess Margaret Cancer Centre, University of Toronto, Canada
236	<b>The risk of haemorrhage with the use of fluoxetine in the patients aged 60 years and older using KAERS database</b> Seonji Kim, Seoul National University, South Korea
<b>E. Evidence-based medicine</b>	
248	<b>Analysis of the efficacy and safety of remifentanyl and fentanyl in abortion: a systematic review and meta-analysis</b> Shiyang Liu, Chinese Academy of Medical Sciences and Peking Union Medical College, China
249	<b>The effect of fixed combination of valsartan-amlodipine on the primary hypertension: a systematic review and meta-analysis</b> Jian Gong and Wen Pan, Liaoning Center for Disease Control and Prevention and Shenyang Pharmaceutical University, China
250	<b>Limited knowledge of chronic kidney disease among high-risk diabetic and hypertensive patients in India: evidence from a cross-sectional study</b> Salman Hussain, Jamia Hamdard, India
251	<b>Association between hemoglobin A1c levels and ischemic stroke events: a systematic review and meta-analysis</b> Surasak Saokaew, University of Phayao, Thailand
252	<b>Impact of incretin-based therapies on arthralgia among type 2 diabetes: a systematic review and network meta-analysis</b> Shuqing Yu, Le Gao and Feng Sun, Peking University School of Public Health, China
253	<b>The hypoglycemia safety of dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes mellitus: a systematic review and network meta-analysis</b> Baoqi Zeng, Peking University, China
254	<b>Comparative efficacy and safety of hydromorphone and morphine in post-cesarean section analgesia: a systematic review and meta-analysis</b> Su Xiawen, Chinese Academy of Medical Sciences and Peking Union Medical College, China
255	<b>Biomedical and therapeutic predictors of survival time and mortality of adult HIV/TB co-infections; a retrospective cohort study</b> Nigatu Tadesse, Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Ethiopia
256	<b>The association between HPV and prognosis of unknown primary carcinoma in head and neck region: a systematic review and meta-analysis</b> Jianjun Ren, Princess Margaret Cancer Centre, University of Toronto, Canada
257	<b>Efficacy and safety of biosimilar drugs compared to reference biologics in oncology: systematic review and meta-analysis of RCTs and NRCTs</b> Ji Chun Yang, Peking University, China

Poster number	Paper title and presenter
258	<b>Epidemiological characteristics of hospitalized patients with complicated intra-abdominal infection: a cross-sectional analysis using electronic medical records</b> Yanmei Liu, West China Hospital, Sichuan University, China
259	<b>A database study to estimate the background incidence of intussusception in Liujiang County, China</b> Tengfei Man, MSD R&D, China
260	<b>The methodological research on dose-effect adjustment in network meta-analysis: a simulation and application study</b> Lin Zhuo, Peking University, China

## G. Drug utilization evaluation studies

269	<b>Review of the drug utilization researches of outpatient antibiotics in China</b> Houyu Zhao, Peking University, China
270	<b>Outpatient parenteral antibiotic use in China: a nationwide descriptive analysis</b> Houyu Zhao, Peking University, China
271	<b>Outpatient quinolone use in China</b> Lu Xu, Peking University, China
272	<b>Prescription drug among patients with dengue fever in Japan: results from National Claims Database</b> Yusuke Kajimoto, Tokyo University, Japan
273	<b>Prescription patterns and appropriateness of topical mupirocin in ambulatory care using the Korean national health insurance claims database</b> Eun Young Kim, Chung-Ang University, South Korea
274	<b>Real world second- and later-line treatment regimens for relapsed/refractory small cell lung cancer in Germany and the United States</b> Rui Jiang, AbbVie Inc, USA
275	<b>Treatment pattern of patients with locally advanced and metastatic melanoma in a real-world setting in China</b> Shusen Liu, MSD Pharmacoepidemiology AP Unit, China
276	<b>Cost effectiveness analysis of pembrolizumab in cancer therapy: a systematic review</b> Lori Ann Foster and Claudette Donatien, Touro College of Pharmacy, USA
277	<b>Adherence and concomitant medication use among persons on warfarin therapy: insight from large pharmacy dispensing database in Japan</b> Masato Takeuchi, Kyoto University, Japan
278	<b>Utilization of the beliefs about medicine questionnaire and prediction of medication adherence in China: a systematic review and meta-Analysis</b> Bo Nie, UCL School of Pharmacy, UK
280	<b>Drug utilization research of antihypertensive drugs for hospitalized patients with hypertension in Shenyang</b> Jian Gong and Wen Pan, Liaoning Center for Disease Control and Prevention and Shenyang Pharmaceutical University, China
281	<b>Joint considerations of safety and efficacy for expansion cohorts in phase I drug trials</b> Xian Jin Xie, University of Iowa, USA
282	<b>A nationwide follow-up study to investigate the patterns of use of long-acting bronchodilators in patients with COPD in New Zealand</b> Jiaxu Zeng, University of Otago, New Zealand
283	<b>Drug utilization trend of monoclonal antibody in China: 2013-2016</b> Ruixue Bie, The University of Macau, China

## I. Pharmacoepidemiology and traditional medicines

294	<b>Detecting drug-herbal interaction by analysis of spontaneous reporting system: an example of anaphylaxis and concomitant use of ribavirin and qingkailing</b> Haona Li, Fourth Military Medical University, China
295	<b>Traditional Chinese Medicine and drug-induced anaphylaxis: data from the Beijing Pharmacovigilance Database</b> Xiaotong Li, Peking University Third Hospital, China
296	<b>Comparative effectiveness of integrated traditional Chinese Medicine in management of chronic neurogenic pain</b> Hanwen Zhang, Australian National University, Australia
297	<b>Incidence rates of health outcomes of interest among Chinese children: a retrospective cohort study using population-based electronic health records</b> Xiaofeng Zhou, Pfizer Inc, USA
298	<b>Risk association of antihypertensive medications, lipid profiles and new onset-diabetes in Thais</b> Sawaeng Watcharathanakij, Ubon Ratchathani University, Thailand



Poster number	Paper title and presenter
299	<b>Factors associated with drugs prescribing for common childhood diseases in a developing country: a population-based study</b> Naima Ahmed Tamanna, Jagannath University, Bangladesh
300	<b>10-year dynamics of reception frequency, used doses of original and generic forms of main drug groups within the CHD registry</b> Svetlana Tolpygina, National Medical Research Center for Preventive Medicine, Russian Federation
301	<b>10-year dynamics of reception of statins within the coronary heart disease registry</b> Svetlana Tolpygina, National Medical Research Center for Preventive Medicine, Russian Federation

## Monday 29 October 2018

Poster number	Paper title and presenter
<b>B. Post-marketing drug effectiveness and safety evaluation</b>	
213	<b>The risk of mortality associated with haloperidol compared with other antipsychotics: propensity-score-matched cohort study in Hong Kong</b> Angel YS Wong, London School of Hygiene and Tropical Medicine, UK
214	<b>The risk of cardiovascular events among antipsychotic-treated patients with schizophrenia in Japan</b> Darmendra Ramcharran, Janssen Research & Development (J&J), USA
215	<b>Novel adverse events of iloperidone: a disproportionality analysis of US Food and Drug Administration Adverse Event Reporting System (FAERS) database</b> Subeesh Viswam, M.S. Ramaiah University of Applied Sciences, India
216	<b>Analysis of eperisone induced adverse drug reactions using data from Korean pharmacovigilance system</b> Jung-Won Park, Yonsei University College of Medicine, South Korea
217	<b>Monitoring real world Prevenar 13 safety in China: a population-based cohort study with hybrid data collection methods and outcome validation</b> Kui Huang, Pfizer Inc, USA
218	<b>Feasibility assessment for an observational study evaluating effectiveness/safety of a fifth-generation cephalosporin antibiotic in community-acquired pneumonia (CAP) patients in China</b> Yun Gu, Pfizer Inc, USA
219	<b>Comparing the therapeutic role of Antiviral Ledipasvir/Sofosbuvir versus interferon injections and protease inhibitors in the treatment of Hepatitis C</b> Irfan Khan, Touro College of Pharmacy, USA
220	<b>Treatment adherence and factors affecting it in patients with stable angina pectoris during therapy with nicorandil</b> Yulia Lukina, National Medical Research Center for Preventive Medicine, Russian Federation
221	<b>Acarbose treatment and the risk of coronary heart disease in patients with type 2 diabetes: a cohort study</b> Yixin Sun, Peking University, China
222	<b>Comparison of medication strategy revise in newly-diagnosed type 2 diabetes patients using generics or brand-name acarbose</b> Yifan Zhou, Peking University, China
223	<b>Comparative effectiveness and safety of Ticagrelor versus Prasugrel following acute percutaneous coronary intervention</b> Nicholas Belviso, University of Rhode Island, USA
224	<b>Prevalence of adverse drug reactions of herbal medicines in Udupi region in Karnataka</b> Bhavana Bhat, Manipal College of Pharmaceutical Sciences, India
<b>D. Pharmacogenomics research and drug safety</b>	
237	<b>Association of Interleukin-4 and Interleukin-10 polymorphisms with Cyclosporine drug-induced hepatotoxicity in Chinese renal transplant recipients</b> Al Yangwen and Xin Huawen, Chinese People's Liberation Army Wuhan General Hospital, China
238	<b>Association of ABCG2 421C&gt;A polymorphisms with adverse reactions caused by mycophenolate mofetil in kidney transplant recipients</b> Di Du and Huawen Xin, Wuhan General Hospital of Guangzhou Military Command, China
239	<b>Fc-γ receptor polymorphisms and overall survival in colorectal cancer patients treated with cetuximab: an assessment of mediation by cetuximab pharmacokinetics</b> Lidija Latifovic, Princess Margaret Cancer Centre, University of Toronto, Canada
240	<b>The association of FCGR2A and FCGR3A polymorphisms with clinical outcomes in cetuximab-treated patients with metastatic colorectal cancer</b> Lidija Latifovic, Princess Margaret Cancer Centre, University of Toronto, Canada



Poster number	Paper title and presenter
241	<b>Literature review on prevalence of PD-L1 expression among Chinese non-small-cell lung cancer patients</b> Jianghui Zhu, MSD R&D, China
242	<b>Association of two BRM promoter polymorphisms and tobacco exposure with malignant pleural mesothelioma (MPM) risk and survival</b> Geoffrey Liu, Princess Margaret Cancer Centre, University of Toronto, Canada
243	<b>The effect of WFS1 and ABCC2 heritable variants on cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients</b> Geoffrey Liu, Princess Margaret Cancer Centre, University of Toronto, Canada
244	<b>Two BRM promoter polymorphisms do not predict susceptibility or prognosis of thymoma</b> Geoffrey Liu, Princess Margaret Cancer Centre, University of Toronto, Canada
245	<b>The antiphospholipid antibody syndrome and risk of newonset thrombosis: a cohort study using laege claim database in Japan</b> Sachiko Tanaka, Shiga University, Japan
246	<b>Cefoperazone/Sulbactam-associated coagulopathy and bleeding</b> Chen Pan, Beijing Friendship Hospital, Capital Medical University, China

## F. Evidence-based pharmacy

261	<b>Impact of gene polymorphisms involved in folate metabolism on methotrexate toxicity in osteosarcoma: a systematic review and meta-analysis</b> Zai-wei Song, Peking University Third Hospital, China
262	<b>Effects of combined medication on the safety of high-dose methotrexate: a systematic review</b> Shuang Liu, Peking University Third Hospital, China
263	<b>The comparative nephrotoxicity potential of colistin and polymyxin B: a meta-analysis</b> Guangyao Li, Peking University, China
264	<b>Rapid advice guidelines for the pharmacological management of human albumin in patients with liver cirrhosis</b> Huibo Li, Peking University Third Hospital, China
265	<b>Menatetrenone (vitamin K2) in the management of osteoporosis: rapid health technology assessment</b> Na He, Peking University Third Hospital, China
266	<b>Association of hormone replacement therapy with risk of dementia in post-menopausal women: a meta-analysis for observational study</b> Chen-Pei Ho and Jer-Fu Lee, Buddhist Tzu Chi General Hospital, Taiwan
267	<b>Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles</b> Zhan-Miao Yi, Peking University Third Hospital, China
268	<b>Evaluation of current guidelines for using antifungal agents in adult non-neutropenic critically ill patients: using the AGREE II instrument</b> Yan Wang, The University of Queensland, Australia

## H. Rational drug use

284	<b>Discharge prescribing in older adults with type 2 diabetes hospitalised for diabetes-related complications</b> Claire Keen, Monash University, Australia
285	<b>Hypoglycaemia hospitalisation cost and length of stay in patients with diabetes mellitus: a cross-sectional study</b> Abdallah Y Naser, University College London, UK
286	<b>A review of 2017 "Real World" evidence literature in Asia</b> Mary Ritchey, RTI Health Solutions, USA
287	<b>Empirical investigation on Chinese pharmaceutical listed companies' environmental disclosure</b> Zhiting Liu, University of Macau, China
288	<b>Can health care utilization of 1/5 Chinese be protected? – analysis of inpatients of floating population in Jiangsu</b> Xinzhaoh Cai, University of Macau, China
289	<b>Exploration of self medication practice in general public of Pokhara Lekhnath city, Nepal</b> Sabita Paudel, Gandaki Medical College Teaching Hospital, Nepal
290	<b>A study to assess the pharmacist based education in improving the safe and quality use of vaccines</b> Juny Sebastian, JSS College of Pharmacy, JSS Academy of Higher Education & Research, India
291	<b>Antibiotic prescription for acute upper respiratory tract infections in tertiary hospitals in China</b> Jingnan Feng, Peking University School of Public Health, China
292	<b>Pharmacoepidemiology on antibacterials for inpatients with chronic obstructive pulmonary disease exacerbations in Pudong new area</b> Jian Gong and Wen Pan, Liaoning Center for Disease Control and Prevention and Shenyang Pharmaceutical University, China
293	<b>Clinically Significant Drug Interactions (CSDIs) in Seropositive HIV patients</b> Umesh Marappa, JSS College of Pharmacy, JSS Academy of Higher Education & Research, India